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Supplemental Material 
Determination of gene and interval copy number by FCGR locus paralogue ratio test 
In a paralogue ratio test (PRT), one pair of primers amplifies two regions of the genome in a single 
PCR reaction (Fig. S1A): typically one is a region to be tested for CNV, and the other is a reference 
locus. The two PCR products differ in size by a small number of nucleotides, and can be resolved 
by capillary electrophoresis (Fig. S1B).  The relative intensity of the bands of product from the 
CNV locus versus the reference locus is proportional to the relative diploid gene copy numbers at 
the two genomic locations – for instance if the reference locus is invariant (two copies in the diploid 
genome) and there is twice as much of the CNV locus product, it can be extrapolated that there are 
four copies of the CNV region.  
 
Two PRT assays were developed in this study. The first, PRT-3B/3A, amplified a region in both 
FCGR3B and FCGR3A, and the second, PRT-2C3’/2A3’, amplified a region in the 3’ untranslated 
regions of both FCGR2C and FCGR2A (Fig. 1 and Fig. S1A). A third primer pair, PRT-
3(A+B)/Chr18, was based on a published assay (1), and amplified a region of the same length in 
both FCGR3A and FCGR3B, and a third region of a slightly different length in Chromosome 18 
(4149307-4149392, hg18, Fig. 1). By combining the three PRTs, no restriction digest was required 
to determine FCGR3A and FCGR3B relative CN, as previously required (1). At the start of this 
study, FCGR2C and FCGR3B were thought to be under copy number variation, and the copy 
number status of FCGR2A and FCGR3A was undetermined. 
 
The integer diploid CN at each locus interrogated by a PRT assay can be determined from the 
relative amount of product amplified from each locus. To determine the CN at the amplified region 
in FCGR3B, for instance, the intensity of the signal of the FCGR3B product was first divided by 
that of FCGR3A (Fig. S1B).  This value was consistent upon replication (Fig. S2A). The value was 
then related to the underlying gene CN. For instance, consider an individual in whom there is no 
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variation in the copy number at any of the amplified FCGR loci, i.e. two copies of each locus in a 
diploid individual.  If the amount of product amplified from FCGR3B was divided by that from 
FCGR3A, the result would be 1. Similarly, FCGR2C 3’UTR / FCGR2A 3’UTR would be 1. In an 
individual, however, in which the FCGR3B diploid CN is 3 and FCGR3A remains invariant, 
FCGR3B / FCGR3A ~1.5. Similarly, if there is a single FCGR3B deletion (CN is 1) and FCGR3A 
remains invariant, FCGR3B / FCGR3A = 0.5 (Fig. S1B,C).  
 
If two genes lie within the same CN variable region, PRT assays which compare them to loci 
outside this region should produce the same result. In the majority of individuals, when FCGR3B / 
FCGR3A ~1.5, FCGR2C / FCGR2A was also ~1.5 (Fig. S2C). Indeed FCGR3B / FCGR3A was 
consistently similar to FCGR2C 3’UTR / FCGR2A 3’ UTR, and when the two PRT assays 
measuring these loci were plotted against each other, the points lay on the diagonal (Fig. S2C). This 
implied that the PRT amplification sites in FCGR3B and FCGR2C fall within the same CN variable 
region – designated CNR1 (Fig. 1 and Fig. S1D, blue).  
 
The fact that FCGR3B / FCGR3A was similar to FCGR2C 3’UTR / FCGR2A 3’ UTR in most 
individuals meant that the two PRT assays measuring these loci act as replicate assays for CN 
variation in CNR1. When plotted against each other, data clusters representing groups of 
individuals with the same underlying diploid CN variations in the FCGR locus could be 
distinguished. The largest of these groups (corresponding to FCGR3B:FCGR3A of 1:2, 2:2 or 3:2) 
were differentiated reliably using a clustering algorithm (Fig. S2B, Table S8), although the more 
diffuse or smaller clusters, such as FCGR3B:FCGR3A of 4:2, were unable to be clustered by the 
algorithm and had to be designated manually (Table S8).  
 
Although many clusters could be explained by variation in the number of copies of CNR1 (Fig. S1C 
and Fig. S2C, blue), the cluster in which both FCGR3B / FCGR3A ~0.6 and FCGR2C 3’UTR / 
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FCGR2A 3’ UTR ~0.6 could only be explained by three copies of FCGR2A 3’UTR and FCGR3A, 
with CNR1 invariant (Fig. S1C and Fig. S2C, red). This indicated a second CN variable region, 
CNR2 (Fig. 1 and Fig. S1D, red).  Clusters which represented a single duplication in CNR1 and 
deletion in CNR2, or vice versa, were also observed (Fig. S1C and Fig. S2C, purple). 
 
The cluster in which FCGR3B / FCGR3A = 2 could be explained in two ways:  four copies of 
FCGR3B and invariant FCGR3A, or invariant FCGR3B and one copy of FCGR3A. These two 
possibilities could be distinguished by their total CN of FCGR3. A third assay, PRT-3(A+B)/Chr18, 
which compared the total FCGR3 copy number to a region in chromosome 18, was therefore used 
to distinguish these two possibilities by manual calls, as well as improving the resolution of the 
other minor clusters (Fig. S1C and Fig. S2D). Manual calls were also required to distinguish these 
minor clusters. For instance, individuals with FCGR3B: FCGR3A CN of 2:3 were typically called 
as 1:2 by the clustering algorithm (Table S8).  These calls were reliable: in replicate assays using all 
three PRTs on a set of Hong Kong Chinese samples, less than 3% of final CN designations made in 
one replicate changed in the second. Nearly all of the samples which failed in one replicate were 
able to receive a CN designation in the other (Table S8).  
 
Not all potential combinations of relative FCGR3B and FCGR3A CN could be identified. Two 
combinations, FCGR3B:FCGR3A CN of 1:1 and 3:3, were indistinguishable from 
FCGR3B:FCGR3A CN of 2:2, despite the fact that they should be able to be discriminated on total 
FCGR3 number. This was likely due to the variability in the PRT-3(A+B)/Chr18 assay and the fact 
that the 1:1 and 3:3 individuals were much rarer.  Others, such as FCGR3A 0CN, may be too rare to 
be identified reliably. For a small percentage of individuals, no FCGR CN could be determined, 
reflecting either variability in the assay or very rare underlying CN combinations (Fig. S2F, Table 
S8). 
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In South East Asians a cluster in which FCGR3B / FCGR3A ~0.6 and FCGR2C 3’UTR / FCGR2A 
3’ UTR ~1.5 was identified (Fig. S1C and Fig. S2E, green). This represented three copies of 
FCGR3A and FCGR2C including the 3’UTR, with invariant FCGR2A 3’UTR and FCGR3B. This 
variation indicated the presence of a third CNV region, CNR3 (Fig. 1 and Fig. S1D, green) 
incorporating FCGR3A and FCGR2C 3’UTR. Individuals with a deletion in CNR3 were not 
identified, but may be rare.  
 
CNR1 and CNR2 are comparable to two CNV regions previously identified using MLPA with 
multiple probes in each gene in the low affinity FCGR locus (2, 3). The most common CNV region, 
CNR1, included the PRT primer binding sites in the middle of FCGR3B and in the 3’ UTR of 
FCGR2C. The MLPA studies supported a CNV region encompassing all of FCGR2C and FCGR3B, 
equivalent to CNR1. No CNV was reported in FCGR2B. The second region, CNR2, included the 
PRT primer sites in the 3’UTR of FCGR2A and the middle of FCGR3A. The MLPA studies report a 
CNV region encompassing FCGR2C and FCGR3A, as well as HSP6 which lies between FCGR2A 
and FCGR3A. Combined with our findings, it suggested that the true extent of CNR2 runs from 
within the 3’ end of FCGR2A, in which our PRT primer in falls closer to the end of FCGR2A than 
the last MLPA probe, through to the end of FCGR2C prior to the PRT 3’UTR binding site (Fig. 1). 
The final region, CNR3, was primarily observed in the Vietnamese and Chinese cohorts, and only 
individuals with a duplication in this interval were identified (Fig. S2E, Table S1). It incorporated 
FCGR3A and FCGR2C including the 3’UTR, but did not extend to the 3’UTR of FCGR2A. This 
region had not previously been identified. 
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Figure S1: Diagram of FCGR paralogue ratio test assay 
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Figure S2: Replication and clustering of PRT assay results 
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A) The same genomic samples were amplified twice using paralogue ratio test PRT-3B/3A primers, 
and the relative amounts of product (FCGR3B / FCGR3A) for the replicated assays were plotted 
against each other. There was a strong correlation between the replicate experiments. R2=0.8714. B) 
Relative product amounts of FCGR3B / FCGR3A (from PRT-3B/3A assay) and FCGR2C 3’UTR / 
FCGR2A 3’UTR (from PRT-2C3’/2A3’ assay) were plotted against each other to improve 
discrimination of CN ratio groups. After normalisation with controls, the data were clustered using 
a mclust algorithm with 95% confidence. Points which did not fall within a cluster were designated 
with an x. Clusters discriminated using the algorithm represent FCGR3B:FCGR3A copy number 
ratios of 3:2 (green), 2:2 (blue), and combined 1:3 + 1:2 + 2:3 (red). This cohort: UK Caucasian 
controls. C) Typically, values for FCGR3B / FCGR3A and FCGR2C 3’UTR / FCGR2A 3’ UTR 
were the same. Clusters were distinguished, and relative copy number of genes was assigned in 
conjunction with D), where clusters could be further discriminated by comparing FCGR3B / 
FCGR3A and FCGR3 / Chr18. Clusters corresponding to FCGR3B:FCGR3A copy number ratios of 
0:2, 1:3, 2:3, 2:1, and 4:2 were identified manually by researchers blinded to cohort. Variation in 
CNV regions producing the observed gene copy number could be inferred: blue, variation in CNR1; 
red, in CNR2; purple, in CNR1 and CNR2. This cohort: UK Caucasian controls. E) Duplication of 
the novel CNR3 interval (green) was identified where FCGR3B / FCGR3A and FCGR2C 3’UTR / 
FCGR2A 3’UTR differed, primarily in Asian cohorts. This cohort: Vietnamese controls. F) 
Percentages of each cohort in which copy number was able to be designated (white) or either a PCR 
failed (diagonal lines) or designation was not possible (black). 
 
 8
 Table S1: Ethnic profiles of CN interval variation in control cohorts 
CN region UK Caucasian 
Hong Kong 
Chinese Vietnamese Kenyan 
CNR1 CNR2 CNR3     
0,1 2 2 103   (6.9) a 93   (9.4) 86   (9.7) 151   (18.1) 
3,4 2 2 166   (11.2) 138   (13.9) 121   (13.6) 54   (6.4) 
2 1 2 18   (1.2) 7   (0.7) 8   (0.9) 3   (0.3) 
2 3 2 60   (4.0) 25   (2.5) 33   (3.7) 13   (1.5) 
1 3 2 7   (0.47) 4   (0.4) 4   (0.4) 1   (0.1) 
3 1 2 2   (0.13) 0   (0) 2   (0.2) 1   (0.1) 
2 2 3 8   (0.54) 22   (2.2) 39   (4.4) 1   (0.1) 
2 2 2 1120   (75.5) 700   (70.7) 592   (66.8) 609   (73.1) 
 Total 1484 989 885 833 
 
Abbreviations: CN, diploid copy number of region; CNR1, CN variable region including FCGR2C 
and FCGR3B; CNR2, CN variable region including FCGR2A3’, FCGR3A and FCGR2C (not 
including 3’ UTR); CNR3, CN variable region including FCGR3A and FCGR2C (including 3’ 
UTR). 
Bold: variation of CN in the interval. 
a: counts (percentages).  
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Table S2:  Association of FCGR3A CN with autoimmunity and infection 
Abbreviations: CNV, copy number variation; 3 vs 12, comparison of three copies (diploid) of 
FCGR3A versus 1 or 2 by Fisher’s exact test; OR, odds ratio; CI, confidence interval; p, 
significance level of Fisher’s exact test;  
a counts (percentages) 
 Hong Kong Chinese   UK Caucasian   Swedish Caucasian  
FCGR3A Control a SLE  Control SLE  Control SLE 
1 7    (0.7) 6   (0.7)  20   (1.3) 3   (1.4)  4   (1.4) 1   (0.4) 
2 931    (94.1) 835   (94.9)  1389   (93.7) 198   (94.3)  260   (93.5) 231   (96.3) 
3 51    (5.2) 39   (4.4)  75   (5.1) 9   (4.3)  13   (5.0) 8   (3.3) 
TOTAL 989 880  1484 210  277 240 
         
p 3 vs 1,2  0.51   0.74   0.39 
OR   1.17   1.19   1.54 
[95% CI]  [0.76-1.80]   [0.59-2.41]   [0.64-3.74} 
         
 Vietnamese   Kenyan   Kenyan  
 Control Malaria  Control Malaria   Sepsis 
1 10   (1.1) 6   (1.5)  4   (0.4) 6   (0.4)   1   (0.1) 
2 799   (90.2) 351   (92.6)  814   (97.7) 1198   (97.9)   910   (96.5) 
3 76   (8.5) 22   (5.8)  15   (1.8) 19   (1.5)   32   (3.3) 
TOTAL 885 379  833 1223   943 
         
p 3 vs 1,2  0.11   0.80   0.039 
OR   0.66   0.86   1.92 
[95% CI]  [0.40-1.072]   [0.43-1.70]   [1.03-3.56] 
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Table S3: FCGR2B-I232T and SLE 
FCGR2B  Hong Kong Chinese       
I232T Control a SLE  SLE+nephrits SLE-nephritis   
TT 57   (5.6) 60   (7.3)  20   (6.3) 40   (8)   
IT 404   (39.4) 284   (34.7)  117   (37.1) 167   (33.2)   
II 565   (55.1) 475   (58)  179   (56.6) 296   (58.8)   
Total 1026 819  316 503   
        
T allele 0.252 0.247  0.248 0.246   
I allele 0.748 0.753  0.752 0.754   
        
p HW  0.382 0.160  0.989 0.066   
         
p TT vs IT/II  0.13  0.58 0.07   
OR   1.34   1.15 1.47    
[95% CI]  [0.92-1.96]  [0.68-1.94] [0.97-2.23]   
p  TT vs IT vs II  0.06  0.7 0.03   
              
FCGR2B  Swedish Caucasian  UK Caucasian  
 Combined 
Caucasian b 
I232T Control SLE   Control SLE   
TT 11   (3.9) 23   (8.9)  11   (2.5) 12   (5.8)   
IT 49   (17.2) 60   (23.3)  81   (18.3) 41   (19.8)   
II 225 176   (67.7)  351   (79.2) 154   (74.4)   
Total 285 259  443 207   
        
T allele 0.125 0.206  0.116 0.157   
I allele 0.875 0.794  0.884 0.843   
        
p HW 0.002 2.55x10-5  0.068 0.001   
p TT vs IT/II  0.02   0.04  7x10-4   
OR   2.45    2.42   2.62 
[95% CI]  [1.17-5.13]   [1.05-5.57]  [1.52-4.52] 
p  TT vs IT vs II  0.01     0.08  2x10-4 
Abbreviations: SLE, systemic lupus erythematosus; p, significance of Fisher’s exact test (TT vs 
II/IT) or chi squared test of independence (TT vs II vs IT); OR, odds ratio; CI, confidence interval; 
HW, p-value for the test of Hardy-Weinberg equilibrium; 
a counts (percentages).  
b Combined Caucasian cohort: sum of individuals from Swedish and UK cohorts 
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Figure S3: Meta-analysis of Caucasian FCGR2B-I293T  
Meta-analysis (random effects model) of the association of homozygotes of the FCGR2B non-
inhibitory allele (TT) versus the remainder (IT/II) between Caucasian systemic lupus erythematosus 
(SLE) cases and controls from the literature (4-6) and current cohorts in this study. Bars are 
proportional to study size. This study: green bars. SW, Swedish.  
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Figure S4: Distribution of FCGR2A and FCGR2B diplotypes over copy number groups  
The percentage of FCGR2A-R131H and FCGR2B-I232T diplotypes in individuals stratified by 
FCGR3B copy number in a Hong Kong Chinese control population. This shows increased numbers 
of SLE risk genotype FCGR2B-232T/T individuals in the FCGR3B low copy number group, but 
increased SLE risk genotype FCGR2A-131R/R in the FCGR3B high copy number group.  
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Table S4:  Linkage disequilibrium in the FCGR locus 
 FCGR Kenyan a,b 
Hong Kong 
Chinese Vietnamese UK Caucasian 
Swedish 
Caucasian 
SNPxSNP n P (cor) n P (cor) n P (cor) n P (cor) n P (cor) 
3A-VF 2A-RH 304 < 0.0001 292 0.0131 298 0.3080 315 0.0004 160 <0.0001 
3A-VF 2B-IT 296 < 0.0001 318 0.0025 297 0.0178 335 0.9465 171 0.0584 
2A-RH 2B-IT 295 0.0072 295 0.0075 302 0.0003 314 0.2412 160 0.0291 
  r2 D' r2 D' r2 D' r2 D' r2 D' 
3A-VF 2A-RH 0.094 0.421 0.020 0.155 0.005 0.090 0.043 0.278 0.0967 0.409 
3A-VF 2B-IT 0.049 0.533  0.031 0.380 0.021 0.295 0.00002 0.015  0.0139 0.403 
2A-RH 2B-IT 0.020 0.248  0.020 0.338  0.039 0.513 0.0073 0.223 0.0268 0.424 
                      
SNPxCNV n P (cov) n P (cov) n P (cov) n P (cov) n P (cov) 
3A-VF 3B CNV 307 0.767 319 0.288 302 0.311 340 0.967 174 0.012 
2A-RH 3B CNV 306 0.183 296 0.041 307 0.265 317 0.412 163 0.450 
2B-ITc 3B CNV 803 0.713 975 0.020 700 0.337 365 0.026 178 0.023 
  r2 D' r2 D' r2 D' r2 D' r2 D' 
2B-ITc 3B HCN 0 0.000 0.100 0.002 0.096 0.002 0.113 0.002 0.083 0.007 0.158 
 3B HCN 1 0.000 0.029 0.002 0.171 0.002 0.060 0.000 0.132 0.005 0.084 
 3B HCN 2 0.005 0.231 0.007 0.493 0.000 0.023 0.003 0.565 0.000 0.019 
            
Abbreviations: FCGR, Fc gamma receptor; 2A-RH, FCGR2A-R131H; 3A-VF, FCGR3A-V176F; 
2B-IT, FCGR2B-I232T; 3B-CN, FCGR3B copy number; P(cor), p value associated with correlation 
of SNP genotypes; P(cov), p value determined by covariance of SNP and CNV genotypes; D’ and 
r2, LD measures derived from phased haplotypes;  
3B HCN 0, LD measured between diallelic SNP and phased haplotype copy number of deletion vs 
duplication/normal; 3B HCN 2, LD measured between SNP and duplication vs deletion/normal. 
a All individuals are from the control cohorts used in association studies 
b FCGR3A CN=2 except where noted.  
c All FCGR3A CN.  
Bold: D’ was considered appreciable if >0.25 and p values significant at 95% level 
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Table S5: FCGR2A-R131H, FCGR3A-V176F, and SLE 
 Hong Kong Chinese  UK Caucasian  Swedish Caucasian 
 Control a SLE    Control  SLE    Control  SLE   
FCGR2A-R131H            
R/R 34 (10.3) 45 (13.2)  101 (28.4) 47 (35.3)  52 (28.2) 77 (33.6) 
R/H 152 (46.2) 156 (45.8)  177 (49.8) 60 (45.1)  86 (46.7) 103 (45.5) 
H/H 143 (43.4) 139 (40.8)  77 (21.6) 26 (19.5)  46 (25) 47 (20.7) 
Total 329  340   355  133   184  227  
HW 0.79  0.99   1.0  0.69   0.68  0.55  
p R/R vs. R/H+H/H 0.281     0.151     0.284  
Odds ratio [95% CI] 1.32 [0.82-2.13]   1.37 [0.90-2.10]  1.29 [0.84-1.96] 
      Caucasian combinedb: p=0.065; OR=1.3 [0.98=1.75] 
FCGR3A-V176F            
F/F 133 (37.4) 133 (38.7)  166 (43.7) 78 (44.8)  86 (43.6) 112 (46.4) 
F/V 166 (46.7) 161 (46.9)  178 (46.9) 83 (47.7)  86 (43.6) 99 (41) 
V/V 56 (15.7) 49 (14.2)  35 (9.2) 13 (7.4)  25 (12.6) 30 (12.4) 
Total 355   343     379   174     197   241   
HW 0.94  1.0   0.43  0.36   0.89  0.55  
FCGR3A-V176F, FCGR3A CN=2           
F/F 121 (37.9) 126 (40.9)  149 (43.8) 75 (48.3)  75 (43.3) 103 (46.7) 
F/V 146 (45.7) 140 (45.4)  162 (47.6) 74 (47.7)  76 (43.3) 91 (41.7) 
V/V 52 (16.3) 42 (13.6)  29 (8.5) 6 (3.8)  23 (13.2) 25 (11.4) 
Total 319   308     340   155     174   219   
HW 0.78  0.95   0.26  0.06   0.83  0.79  
p F/F vs. V/F+V/V 0.46     0.38     0.54  
Odds ratio [95% CI] 1.13 [0.82-1.56]   1.20 [0.82-1.76]  1.15 [0.77-1.72] 
       
Abbreviations: SLE, systemic lupus erythematosus; CN, copy number; p, significance of Fisher’s 
exact test; OR, odds ratio; CI, confidence interval; HW, p value for the test of Hardy-Weinberg 
equilibrium. 
a counts (percentages) 
b addition of Swedish and UK Caucasian cohorts 
Bold: low affinity allele homozygote. 
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Table S6: FCGR2A-R131H, FCGR3A-V176F in Kenyan and Vietnamese control cohorts 
 Kenyana Vietnamese  Kenyan Vietnamese  Kenyan Vietnamese 
FCGR2A
-R131H   
FCGR3A
-V176F b    
FCGR2
B-I232T   
R/R 114 (33.1) 37 (10.7) F/F 157 (51.1) 102 (33.7) T/T 28 (8.1) 18 (4.9) 
R/H 169 (49.1) 133 (38.5) V/F 125 (40.8) 150 (49.6) I/T 159 (46.0) 152 (41.0) 
H/H 61 (17.7) 175 (50.7 V/V 25 (8.1) 50 (16.5) I/I 159(46.0) 201 (54.2) 
Total 344 345 Total 307 302 Total 346 371 
a counts (percentages) 
b FCGR3A CN=2 
Bold: low affinity or non-inhibitory allele homozygote. 
 16
Table S7:  FCGR polymorphism diplotype combinations enriched 
 a,b Kenyan Chinese Vietnamese UK Caucasian Swedish Caucasian 
FCGR  O O/E O O/E O O/E O O/E O O/E 
3A-VF 2A-RH           
F/F R/R 71 1.37 9 0.71 9 0.83 52 1.31 28 1.45 
F/F R/H 68 0.91 45 0.89 32 0.81 69 1.00 33 0.99 
F/F H/H 18 0.62 58 1.22 59 1.17 19 0.65 6 0.36 
F/V R/R 29 0.70 18 1.17 16 1.01 32 0.74 15 0.78 
F/V R/H 65 1.09 61 1.00 70 1.21 78 1.04 34 1.02 
F/V H/H 28 1.21 55 0.96 62 0.84 39 1.23 22 1.32 
V/V R/R 1 0.12 6 1.10 7 1.32 6 0.78 2 0.34 
V/V R/H 13 1.09 26 1.20 14 0.73 11 0.82 10 0.98 
V/V H/H 11 2.39 14 0.69 29 1.17 9 1.58 10 1.95 
3A-VF 2B-IT               
F/F T/T 16 1.32 11 1.48 8 1.38 3 1.15 7 1.67 
F/F I/T 81 1.21 50 1.08 45 1.12 27 0.97 14 1.15 
F/F I/I 56 0.77 59 0.88 48 0.89 118 1.01 53 0.92 
F/V T/T 5 0.52 7 0.78 6 0.70 3 1.06 3 0.72 
F/V I/T 46 0.86 58 1.04 61 1.03 30 0.99 10 0.82 
F/V I/I 68 1.18 81 1.00 79 0.99 125 0.99 61 1.06 
V/V T/T 2 1.03 1 0.31 2 0.70 0 0.00 0 0.00 
V/V I/T 4 0.38 13 0.66 14 0.71 6 1.11 4 1.07 
V/V I/I 18 1.56 38 1.32 34 1.28 23 1.02 19 1.07 
2A-RH 2B-IT               
R/R T/T 13 1.65 2 0.96 0 0.00 2 1.25 5 1.99 
R/R I/T 50 1.15 9 0.69 8 0.61 10 0.59 8 1.10 
R/R I/I 37 0.79 23 1.22 24 1.37 79 1.11 31 0.89 
R/H T/T 10 0.88 6 0.72 4 0.59 2 0.72 4 0.92 
R/H I/T 55 0.88 45 0.87 44 0.93 40 1.34 17 1.35 
R/H I/I 75 1.11 83 1.11 69 1.08 115 0.92 56 0.93 
H/H T/T 1 0.23 8 1.02 13 1.48 2 1.70 1 0.46 
H/H I/T 26 1.07 62 1.28 70 1.15 11 0.88 3 0.48 
H/H I/I 28 1.07 57 0.81 70 0.86 53 1.01 36 1.17 
2A-RH 3B-CN           
R/R 01 12 0.60 3 0.84 3 0.78 7 1.01 4 1.22 
R/R 2 80 1.06 23 0.87 19 0.83 67 0.92 34 0.91 
R/R 34 10 1.52 8 1.96 11 1.76 17 1.53 7 1.64 
R/H 01 34 1.18 14 0.99 13 0.93 12 1.00 5 0.88 
R/H 2 106 0.98 105 1.00 85 1.02 131 1.03 67 1.03 
R/H 34 7 0.74 16 0.99 22 0.97 16 0.82 6 0.81 
H/H 01 13 1.16 16 1.20 20 1.11 4 0.79 2 0.71 
H/H 2 42 1.00 103 1.05 111 1.04 57 1.06 33 1.02 
H/H 34 2 0.54 8 0.52 23 0.79 6 0.73 4 1.08 
2B-IT 3B-CN           
T/T 01 4 0.85 1 0.48 4 1.90 2 4.55 4 5.51 
T/T 2 17 0.96 17 1.10 10 0.80 4 0.86 5 0.60 
T/T 34 3 1.94 2 0.83 4 1.17 0 0.00 1 1.05 
I/T 01 28 1.08 15 1.16 16 1.09 4 0.85 0 0.00 
I/T 2 93 0.95 101 1.05 87 1.00 57 1.15 27 1.12 
I/T 34 11 1.29 8 0.54 22 0.93 1 0.13 2 0.73 
I/I 01 26 0.92 18 0.96 17 0.86 19 0.97 9 0.90 
I/I 2 112 1.06 133 0.95 118 1.01 212 1.02 115 1.00 
I/I 34 5 0.54 29 1.34 33 1.03 28 0.88 14 1.07 
Abbreviations: FCGR, Fc gamma receptor; 2A-RH, FCGR2A-R131H; 3A-VF, FCGR3A-V176F; 
2B-IT, FCGR2B-I232T; 3B-CN, FCGR3B copy number; O, observed number; O/E observed 
divided by expected (E calculated by probabilities of individual types multiplied).  
a All individuals are from the control cohorts used in association studies 
b FCGR3A CN=2.  
Grey: increased observed over expected by >1.2x. 
Bold: SLE risk genotypes.  
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Table S8: Concordance of calls in repeated assay of Hong Kong Chinese samples 
Copy number designation b By mclust clustering algorithm:  
FCGR3B: FCGR3A Called c Different call Not clustered d Total 
1st replicate a    364 
0 : 2   4   (100) e 4 
1 : 1 47  (100)   47 
1 : 3  2   (100)  2 
2 : 2 211 (99.1) 1  (0.5) 1  (0.5) 213 
2 : 1   2  (100) 2 
2 : 3  8   (88.9) 1  (11.1) 9 
2 : 3,  2C3 : 2A2   9  (100) 9 
3 : 2 42  (97.7)  1  (2.3) 43 
4 : 2   3  (100) 3 
CN Undetermined f   12  (100) 12  (3.3) 
PRT Fail  g   20  (100) 20  (5.5) 
     
2nd  replicate    364 
0 : 2   5  (100) 5 
1 : 1 40  (97.6)  1  (2.4) 41 
1 : 3  1  (100)  1 
2 : 2 198  (94.3) 2  (1.0) 10  (4.8) 210 
2 : 1   1  (100) 2 
2 : 3  8  (100)  8 
2 : 3,  2C3 : 2A2   8  (100) 8 
3 : 2 46  (97.9)  1  (2.1) 47 
4 : 2   3  (100) 3 
CN Undetermined   13  (100) 13  (3.6) 
PRT Fail   25  (100) 25  (6.8) 
     
2nd replicate 1st replicate 
FCGR3B: FCGR3A CN Same CN Different CN CN Undetermined PRT Fail 
0 : 2 4  (100)    
1 : 2 37  (90.2) 2  (4.9)  2  (4.9) 
1 : 3 1  (100)    
2 : 2 188  (89.5) 4  (1.9) 6  (2.9) 12  (4.7) 
2 : 1 2  (100)    
2 : 3 7  (87.5)   1  (12.5) 
2 : 3,  2C3 : 2A2 5  (62.5) 1  (12.5) 1  (12.5) 1  (12.5) 
3 : 2 42  (89.4) 2  (4.3) 1  (2.1) 2  (4.3) 
4 : 2 3  (100)    
CN Undetermined  11  (78.6) 2  (14.3)   1  (7.1) 
PRT Fail  24  (96.0)  1  (4.0) 
Abbreviations: CN, copy number; PRT, paralogue ratio test; 2C3:2A2, CN of FCGR2C3’=3, 
FCGR2A3’ =2.  
a Full triple PRT assay of 364 Hong Kong Chinese case and control samples, repeated. 
b Diploid CN assigned using both a clustering algorithm and manual calls on data from triple PRT. 
c CN was able to be designated by clustering algorithm, and was unchanged by manual call.  
d Unable to be assigned to a cluster by clustering algorithm. 
e counts (percentages). 
f CN unable to be determined by clustering algorithm or manual call. 
g One or more of the paralogue ratio test products was not amplified. 
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